In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

TASTE: One year outcome of The Thrombus Aspiration in ST-Elevation myocardial infarction in Scandinavia trial

ESC Congress 2014 - Hot Line report

Acute Coronary Syndromes (ACS)



By Bo Lagerqvist, (Uppsala, Sweden)
View Discussant report

Open the Presentation
Watch the Webcast

List of Authors:
Bo Lagerqvist, MD, PhD,1,2), Ole Fröbert, MD, PhD3), Göran K. Olivecrona, MD, PhD 4), Thórarinn Gudnason, MD, PhD 5), Michael Maeng, MD, PhD 6), Ollie Östlund, MSc 2) Stefan K. James, MD. PhD,1,2)
1) Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden
2) Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
3) Department of Cardiology, Örebro University Hospital, Örebro, Sweden.
4) Department of Cardiology, Lund University Hospital Lund, Sweden.
5) Department of Cardiology, Landspitali Univesity Hospital, Reykjavik, Iceland.
6) Department of Cardiology, Skejby Hospital, Aarhus University Hospital, Aarhus, Denmark.


The Thrombus Aspiration in ST-Elevation myocardial infarction in Scandinavia (TASTE trial) randomized 7244 patients undergoing primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) to thrombus aspiration before PCI or PCI alone. The 30-day primary endpoint of all-cause mortality did not differ between the randomized groups. Here we report the preliminary 1-year outcome results.
TASTE introduced the Registry-based Randomized Clinical Trial (RRCT) concept using national registries as on-line platforms for randomization, case record forms and follow-up in Sweden, Denmark and Iceland.
No patients were lost to follow-up for the primary endpoint. All-cause mortality was 5.3% (191 of 3621) in the thrombus aspiration group compared to 5.6% (202 of 3623) in the PCI alone group (hazard ratio (HR) 0.94; 95% confidence interval (CI), 0.78–1.15, P=0.57). Hospitalization for myocardial infarction during one year occurred in 2.7% (96) vs. 2.7% (99) (HR 0.97; 95% CI, 0.73–1.28, P=0.81) and stent thrombosis in 0.7% (27) vs. 0.9 % (32) (HR 0.84; 95% CI, 0.50 - 1.40, P=0.51). The composite of death, myocardial infarction and stent thrombosis occurred in 8.0% (289) vs. 8.5% (307) (HR 0.94; 95% CI 0.80-1.11, P=0.48).
Thrombus aspiration as a routine adjunct to primary PCI does not reduce mortality or ischemic events on long term.


By Gilles Montalescot, FESC (Paris, France)
See Presenter abstract

Open the presentation
Watch the Webcast





Clinical Trial Update Hot Line: Infarction, interventions and outcome

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.